Mylan NV (MYL)

42.16
NASDAQ : Health Care
Prev Close 42.33
Day Low/High 41.76 / 42.35
52 Wk Low/High 33.60 / 50.40
Avg Volume 5.28M
Exchange NASDAQ
Shares Outstanding 535.11M
Market Cap 22.65B
EPS 1.80
P/E Ratio 84.66
Div & Yield N.A. (N.A)

Latest News

Mylan Shares Unchanged as Kaleo Releases EpiPen Competitor

Mylan Shares Unchanged as Kaleo Releases EpiPen Competitor

The Auvi-Q was released Feb. 14, but it's unclear whether patients will break up with their current option, EpiPen, for something new.

Mylan Becomes #29 Most Shorted Nasdaq 100 Component, Replacing Skyworks Solutions

Mylan Becomes #29 Most Shorted Nasdaq 100 Component, Replacing Skyworks Solutions

The most recent short interest data has been released for the 01/31/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

CVS Remains Unsure About the Future of Obamacare, CEO Says

CVS Remains Unsure About the Future of Obamacare, CEO Says

The company had a mixed fourth quarter.

Glaxo Beats Expectations for Fourth-Quarter Earnings; Shares Fall on Advair Concerns

Glaxo Beats Expectations for Fourth-Quarter Earnings; Shares Fall on Advair Concerns

GlaxoSmithKline beat analysts' expectations for fourth-quarter sales and earnings Wednesday but warned of a significant hit this year from anticipated generic competition to its Advair asthma treatment.

Despite Settling Decade-Long Suit, Mylan Shares Fall

Despite Settling Decade-Long Suit, Mylan Shares Fall

Mylan settled a pay-for-delay lawsuit over its narcolepsy drug, but its share prices are falling.

There Is Nothing Generic About the Basing Action on Mylan

There Is Nothing Generic About the Basing Action on Mylan

Prices look set to test key resistance, and this time should see a breakout to the upside.

House Panel to Take Up Trump's Call to Speed FDA Approvals

House Panel to Take Up Trump's Call to Speed FDA Approvals

Generics for drugs facing shortages or having few manufacturers is bill's focus.

Mylan Benefits From Teva's Multiple Sclerosis Patent Dispute Woes

Mylan Benefits From Teva's Multiple Sclerosis Patent Dispute Woes

Mylan's shares rose after Teva's claims of patent infringement were rejected, despite the announcement that the FTC is investigating the drugmaker for antitrust violations.

Mylan's Shares Rise Despite FTC Investigation

Mylan's Shares Rise Despite FTC Investigation

The drug company saw its stock climb 3% Tuesday on news that it can move ahead with generic Copaxone.

Premarket Biotech Movers: Mylan, Momenta Pharmaceuticals, Seres Therapeutics

Premarket Biotech Movers: Mylan, Momenta Pharmaceuticals, Seres Therapeutics

Mylan, Momenta Pharmaceuticals and Seres Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

Express Scripts, Cigna Opt Out of Paying for EpiPen Competitor Auvi-Q

Express Scripts, Cigna Opt Out of Paying for EpiPen Competitor Auvi-Q

It's unclear how much of the hefty $4,500 price pharmacy benefit managers or insurers will agree to pay to keep Auvi-Q free for most patients.

EpiPen Competitor Auvi-Q Will Return in February, but It'll Cost Insurance Companies Big Bucks

EpiPen Competitor Auvi-Q Will Return in February, but It'll Cost Insurance Companies Big Bucks

The autoinjector will be free for insured patients and those whose annual income is less than $100,000.

Biotech Premarket Movers: SGMO, IPXL, PTLA

Biotech Premarket Movers: SGMO, IPXL, PTLA

Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.

Mylan Crushed by Trump, Cigna and CVS -- All In Two Days

Mylan Crushed by Trump, Cigna and CVS -- All In Two Days

The drug maker's shares have fallen 6.2% since Wednesday's market open.

Insulin Drug Offers Hope for MannKind

Insulin Drug Offers Hope for MannKind

The stock has taken a beating, but users of Afrezza are loyal to the drug.

Patent Victory Secures Lilly Hold on Cancer Drug Until 2022

Patent Victory Secures Lilly Hold on Cancer Drug Until 2022

An appeals court in Indiana upheld Eli Lilly's patent regarding Alimta, a major cancer drug for Lilly, keeping Teva and other generic drug specialists at bay.

CVS Is the Latest to Rock Mylan's EpiPen Empire

CVS Is the Latest to Rock Mylan's EpiPen Empire

The price of EpiPens has surged about 25% annually since 2007.

Cigna Will No Longer Cover Mylan's EpiPen

Cigna Will No Longer Cover Mylan's EpiPen

Health insurance giant Cigna said it will no longer cover Mylan's EpiPen.

Cigna Defends Abandoning EpiPen Coverage

Cigna Defends Abandoning EpiPen Coverage

Cigna will now encourage patients to use either Impax's or Mylan's generic autoinjector. Impax offers cheaper prices, but can its manufacturing keep up?

I'd Like to Buy the Country an Aircraft -- ICYMI

I'd Like to Buy the Country an Aircraft -- ICYMI

Donald Trump continued to rip corporate America at a press conference Wednesday, but what else did you missy?

Closing Bell: Volkswagen Secures Plea Deal; Trump Triggers Biotech Selloff

Closing Bell: Volkswagen Secures Plea Deal; Trump Triggers Biotech Selloff

Wall Street secured gains again by late afternoon Wednesday in unpredictable trading following President-elect Donald Trump's first press conference since July.

U.S. FDA Accepts Biologics License Application (BLA) For Mylan And Biocon's Proposed Biosimilar Trastuzumab

U.S. FDA Accepts Biologics License Application (BLA) For Mylan And Biocon's Proposed Biosimilar Trastuzumab

If Approved, MYL-1401O Has Potential To Be the First Biosimilar Trastuzumab in the U.S.

Mylan Expands OTC Offerings by Acquiring Cold-Eeze

Mylan Expands OTC Offerings by Acquiring Cold-Eeze

Cold-Eeze will become Mylan's largest U.S. over-the-counter brand franchise, and builds upon its $1 billion global OTC business.

TheStreet Quant Rating: C (Hold)